The tumor mutation burden was positively correlated with the NQO1 expression levels in cholangiocarcinoma, pancreatic adenocarcinoma, thymoma, glioma, kidney renal papillary cell carcinoma, head and neck squamous cell carcinoma, and negatively correlated in glioblastoma multiforme, acute myeloid leukemia, and prostate adenocarcinoma (Figure 3A). This evidence concerns the gene NQO1 and central nervous system cancer.